5.	Commitments and Contingencies

Leases

We lease

28,275

square feet of laboratory and office space in San Diego, California under a lease which began on

December 1, 2016

and expires on

April 15, 2024.

We have

one

-year option to renew this lease.

We also lease

26,067

square feet of laboratory, office and warehouse space in Redwood City, California and

1,898

square feet of office space in Jersey City, New Jersey. The lease for the Redwood City space expires on

May 31, 2019.

The lease for the Jersey City office space expires on

June 30, 2018.

We believe our facilities are adequate and suitable for our current needs and that we will be able to obtain new or additional leased space in the future when necessary. We also lease certain office equipment under operating lease arrangements.

Annual future minimum lease payments as of

December

31,

2017

are as follows (in thousands):

Year ended December 31:
2018	$	2,418
2019		1,906
2020		1,503
2021		1,546
2022		1,590
Thereafter		2,124
Total future minimum lease payments	$	11,087

Rent expense under all operating leases totaled

$3.1

million,

$2.1

million and

$1.5

million for the years ended

December

31,

2017,

2016

and

2015,

respectively.

Clinical Development Agreements

have entered into agreements with various vendors for the research and development of product candidates, which are generally cancellable anytime at our option. Under the terms of these agreements, the vendors provide a variety of services including conducting preclinical development, conducting research, manufacturing clinical compounds, enrolling and recruiting patients, monitoring studies, data analysis and regulatory filing assistance. Payments under these agreements typically include fees for services and reimbursement of expenses. In addition, under certain agreements, we are subject to penalties in the event we permanently discontinue performance under these agreements.

Purchase Obligations

December

31,

2017,

our purchase obligations of

$39.7

million primarily consisted of commitments with

third

-party manufacturers in connection with the manufacturing of SUSTOL and CINVANTI, as well as commitments with various vendors for sales and marketing support and clinical and preclinical studies. For the year ended

December 31, 2017,

$35.9

million of the total purchase obligations were

not

included in our consolidated financial statements. We intend to use our current financial resources to fund our commitments under these purchase obligations.